Alternative names for L-DOPA antibody
Frozen Sections (C), Enzyme Immunoassay (E), Western blot / Immunoblot (WB), Immunocytochemistry/Immunofluorescence (ICC/IF)
Background of L-DOPA antibody
L Dopa is an intermediate in dopamine biosynthesis. Clinically, L Dopa is used in the management of Parkinson's disease. It is used as a prodrug to increase dopamine levels since it is able to cross the blood-brain barrier whereas dopamine itself cannot. Once L Dopa has entered the central nervous system (CNS), it is metabolised to dopamine by aromatic L amino acid decarboxylase. This also occurs in the peripheral tissues, causing adverse effects and decreasing the available dopamine to the CNS, so it is standard practice to co administer a peripheral DOPA decarboxylase inhibitor and often a catechol-O-methyl transferase (COMT) inhibitor. The antiserum was tested using the free floating PAP technique on rat dopaminergic areas. The anti-conjugated L-DOPA antibodies gave a good staining between 1/2000-1/5000 dilution in these areas.